Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.77 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.77 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.77 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370045 | 1.00 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL5322935 | 0.90 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL19602919 | 0.89 | HSP90AB1 (0.80) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL23384354 | 0.89 | HSP90AB1 (0.80) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL12939036 | 0.88 | HSP90AA1 (0.78) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL5323916 | 0.88 | HSP90AA1 (0.78) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL5323922 | 0.88 | HDAC3 (0.81) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL3957402 | 0.87 | HDAC3 (0.78) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL3959474 | 0.87 | HDAC3 (0.78) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 | |
| SCHEMBL4255576 | 0.87 | HDAC3 (1.00) | HSP90AB1HSP90AA1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| CN-120136941-A | Anti-aging composition and application thereof | 鲁贝多生命科学公司 | 2025-06-13 | — | — | CN | claimed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-10-12 | — | — | US | claimed |
| CN-115381816-A | Application of VER50589 in preparing medicine for resisting enterovirus 71 | 武汉市金银潭医院(武汉市传染病医院) | 2022-11-25 | — | — | CN | claimed |
| US-20220362276-A1 | Small Molecule Inhibitors of Viral Replication | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-11-17 | — | — | US | claimed |
| US-20220273664-A1 | Mitochondrial Targeted Releasable Linker | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-09-01 | — | — | US | claimed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4630004-A1 | TREATMENT OF PROSTATE CANCER HAVING ANDROGEN RECEPTOR VARIANTS | Oric Pharmaceuticals, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250305055-A1 | PROGNOSTIC/PREDICTIVE BREAST CANCER SIGNATURE | CORNELL UNIVERSITY | 2025-10-02 | — | — | US | disclosed |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20100093824-A1 | METHODS OF TREATING VIRAL INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-04-15 | — | — | US | disclosed |
| WO-2008143647-A2 | METHODS OF TREATING VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007096194-A1 | RADIO-LABELED ISOXAZOLE DERIVATIVES USEFUL FOR THE LABELING AND DIAGNOSTIC OF HSP90 FUNCTIONALITY | NOVARTIS AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093824-A1 | METHODS OF TREATING VIRAL INFECTION | EIF2AK2, NSUN2, NSUN3 | HSP90AB1 250/4885HSP90AA1 375/4885HDAC3 632/4885 |
| US-20220362276-A1 | Small Molecule Inhibitors of Viral Replication | HSPH1, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HDAC3 2717/4885 |
| US-20220273664-A1 | Mitochondrial Targeted Releasable Linker | PDF, NDUFAB1, AURKAIP1 | HSP90AB1 866/4885HSP90AA1 1161/4885HDAC3 1942/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885HDAC3 1029/4885 |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | HSP90AB1 296/4885HSP90AA1 240/4885HDAC3 4651/4885 |
| US-20230321130-A1 | Senolytic Compositions and Uses Thereof | SENP3, SENP6, SENP1 | HSP90AB1 620/4885HSP90AA1 517/4885HDAC3 273/4885 |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | HSP90AB1 3057/4885HSP90AA1 3832/4885HDAC3 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.